Fig. 2
From: Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)
Effect of Vascepa on lipid levels in patients with high TG levels (≥200 and <500 mg/dL) despite LDL-C control while on statin therapy in the ANCHOR study. Shown are the median changes from baseline to week 12 in the intent-to-treat population [8]. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol; TG, triglyceride; Total C, total cholesterol